Literature DB >> 7332844

Nortriptyline therapy in elderly patients: dosage prediction from plasma concentration at 24 hours after a single 50 mg dose.

S Dawling, P Crome, E J Heyer, R R Lewis.   

Abstract

Ten depressed elderly female patients in hospital (mean age 82 years) received a single oral dose of 50 mg nortriptyline prior to commencing treatment with this drug. The nortriptyline concentration in a plasma sample obtained 24 hours afterwards was used to predict the daily dose required to achieve a steady-state concentration within the range of 50-150 micrograms. l-1. The mean daily dose prescribed was 50 mg (range 20-100 mg). These dosage regimes provided a mean observed steady-state nortriptyline concentration of 104 micrograms. l-1, with a range of 76-180 microgram. l-1 (S.D. 30 microgram. l-1). Use of this prediction test can prevent the development of toxic plasma concentrations and enhance the possibility of therapeutic success.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332844     DOI: 10.1192/bjp.139.5.413

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Plasma concentrations of mianserin after single dose and at steady-state in depressed elderly patients.

Authors:  S Dawling; S Ford; P Ariyanayagam; H O'Neal; R R Lewis
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

2.  Amitriptyline dosage prediction in elderly patients from plasma concentration at 24 hours after a single 100mg dose.

Authors:  S Dawling; S Ford; D C Rangedara; R R Lewis
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.

Authors:  L L von Moltke; D J Greenblatt; R I Shader
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.